Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Sodium glucose cotransporter-2 inhibitors (SGLT2i) are glucose-lowering therapies with distinct cardiometabolic health benefits. Empagliflozin was shown to reduce risk of cardiovascular death among high-risk patients with type 2 diabetes mellitus [(1)][1], which led to the U.S. Food and Drug
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Arnold, S. V., Inzucchi, S. E., Tang, F., McGuire, D. K., Mehta, S. N., Maddox, T. M., Goyal, A., Sperling, L. S., Einhorn, D., Wong, N. D., et al. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317729252 · Cited by 144
Implications of specialist density for diabetes care in the United States.
Patel, R. B., Al Rifai, M., McEvoy, J. W., & Vaduganathan, M. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3796 · Cited by 28
Cited by
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationSotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Self-citationPrevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999-2020
Ostrominski, J. W., Arnold, S. V., Butler, J., Fonarow, G. C., Hirsch, J. S., Palli, S. R., Donato, B. M. K., Parrinello, C. M., O’Connell, T., Collins, E. B., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.3241 · Cited by 292
Self-citationRangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000920 · Cited by 192
“≥300 mg/g 769 (11) 760 (8) 1169 (7) 3874 (88) .”
Self-citationAdhikari, R., Jha, K., Dardari, Z., Heyward, J., Blumenthal, R. S., Eckel, R. H., Alexander, G. C., & Blaha, M. J. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.023811 · Cited by 166
Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139
Self-citationMahtta, D., Ramsey, D. J., Lee, M. T., Chen, L., Al Rifai, M., Akeroyd, J. M., Vaughan, E. M., Matheny, M. E., Santo, K. R. D. E., Navaneethan, S. D., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1815 · Cited by 137
Dave, C. V., Schneeweiss, S., Wexler, D. J., Brill, G., & Patorno, E. (2020) · Diabetes Care · doi:10.2337/dc19-1943 · Cited by 97
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF
Vaduganathan, M., Fonarow, G. C., Greene, S. J., DeVore, A. D., Kavati, A., Sikirica, S., Albert, N. M., Duffy, C. I., Hill, C. L., Patterson, J. H., et al. (2020) · JACC: Heart Failure · doi:10.1016/j.jchf.2019.12.015 · Cited by 86
Self-citationNelson, A. J., O’Brien, E. C., Kaltenbach, L. A., Green, J. B., Lopes, R. D., Morse, C. G., Al-Khalidi, H. R., Aroda, V. R., Cavender, M. A., Gaynor, T., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.48030 · Cited by 78
Hamid, A., Vaduganathan, M., Oshunbade, A. A., Ayyalasomayajula, K. K., Kalogeropoulos, A. P., Lien, L. F., Shafi, T., Hall, M. E., & Butler, J. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000864 · Cited by 57
Self-citationPrescription of glucagon-like peptide-1 receptor agonists by cardiologists.
Vaduganathan, M., Patel, R. B., Singh, A., McCarthy, C. P., Qamar, A., Januzzi, J. L., Scirica, B. M., Butler, J., Cannon, C. P., & Bhatt, D. L. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.029 · Cited by 55
“However, despite these favorable trends, cardiologists infrequently prescribed either class of therapies in our health system (1).”
BackgroundSelf-citationGunawan, F., Nassif, M. E., Partridge, C., Ahmad, T., Kosiborod, M., & Inzucchi, S. E. (2020) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000195 · Cited by 28
Implications of specialist density for diabetes care in the United States.
Patel, R. B., Al Rifai, M., McEvoy, J. W., & Vaduganathan, M. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.3796 · Cited by 28
Ahmad, A., & Sabbour, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02192-4 · Cited by 25
Disparities in adoption of new diabetic therapies with cardiovascular benefits
Vasti, E. C., Basina, M., Calma, J., Maron, D. J., Rodriguez, F., & Sandhu, A. T. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110233 · Cited by 11
Metadata
- Authors
- Vaduganathan, M., Sathiyakumar, V., Singh, A., McCarthy, C. P., Qamar, A., Januzzi, J. L., Scirica, B. M., Butler, J., Cannon, C. P., & Bhatt, D. L.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 72
- Issue
- 25
- Pages
- 3370-3372
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2900236147
- Cited by
- 123
- References
- 4
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.